Xeroderma pigmentosum (XP) patients with a defect in the nucleotide excision repair gene XPA, develop tumors with a high frequency on sun-exposed areas of the skin. Here we describe that hairless XPA-de®cient mice also develop skin tumors with a short latency time and a 100% prevalence after daily exposure to low doses of U.V.B. Surprisingly and in contrast to U.V.B.-exposed repair pro®cient hairless mice who mainly develop squamous cell carcinomas, the XPA-de®cient mice developed papillomas with a high frequency (31%) at a U.V. dose of 32 J/m 2 daily. At the highest daily dose of 80 J/m 2 mainly squamous cell carcinomas (56%) and only 10% of papillomas were found in XPA-de®cient hairless mice. p53 gene mutations were examined in exons 5, 7 and 8 and were detected in only 3 out of 37 of these skin tumors, whereas in tumors of control U.V.B.-irradiated wild type littermates this frequency was higher (45%) and more in line with our previous data. Strikingly, a high incidence of activating ras gene mutations were observed in U.V.B.-induced papillomas (in 11 out of 14 tumors analysed). In only two out of 14 squamous cell carcinomas we found similar ras gene mutations. The observed shift from squamous cell carcinomas in wild type hairless mice to papillomas in XPA-de®cient hairless mice, and a corresponding shift in mutated cancer genes in these tumors, provide new clues on the pathogenesis of chemically-versus U.V.B.-induced skin carcinogenesis.
Introduction
It is generally accepted that the development of nonmelanoma skin cancer in humans is correlated with exposure to sunlight (IARC Monographs, 1992) . Skin tumor development is a multistep process initiated when genomic DNA is damaged by U.V.-light, and not properly repaired. Following the induction of DNA damage, several cellular processes have been identi®ed to occur, such as accumulation of the p53 protein, overexpression of certain p53-regulated genes, cell cycle arrest, DNA repair, apoptosis and immunological responses (Mukhtar and Elmets, 1996; Kraemer, 1997) . The central role of DNA damage in skin carcinogenesis and the importance of an ecient DNA repair mechanism to eliminate the U.V.-induced DNA damage, is best illustrated by the human heritable disease xeroderma pigmentosum (XP) (Cleaver and Kraemer, 1995) . Seven complementation groups exist in XP (XP-A to XP-G), each caused by a defect in a dierent gene involved in nucleotide excision repair (NER). Due to the inability to repair U.V.-induced lesions, cells isolated from XP patients are highly sensitive to U.V. radiation. Furthermore, XP patients develop skin tumors with an extremely high frequency (41000-fold increase compared to normal individuals). The tumors comprise, like in the general population, mainly basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) at sun-exposed areas of the skin, and melanomas, which are more randomly distributed (Cleaver and Kraemer, 1995) .
Only two of the genetic events that occur in human skin carcinogenesis are known in some detail; i.e. alterations in the p53 tumor suppressor gene and although found at a much lower frequency, in ras oncogenes ( Van der Schroe et al., 1990; Ananthaswamy and Pierceall, 1990; Campbell et al., 1993) . In addition, locations for several putative tumor suppressor genes have recently been identi®ed by LOH analysis (Rees, 1994) . Mutations in the p53 gene have frequently been found in human non-melanoma skin tumors (90% in SCCs and 50% in BCCs) (Brash et al., 1991; Ziegler et al., 1993; Daya-Grosjean et al., 1995; Nataraj et al., 1995; Matsumura et al., 1996; Kraemer, 1997) . In the p53 gene, C?T transitions and CC?TT tandem transitions are almost exclusively observed at dipyrimidine sites. These mutations are thought to display the unique ®ngerprint of DNA damage caused by U.V.B.-irradiation (Bredberg et al., 1986; Dorado et al., 1991; Yagi et al., 1991) . In skin tumors isolated from XP patients, the relative occurrence of these distinctive U.V.-induced CC?TT transitions is even more frequent in the p53 gene (Sato et al., 1993; Dumaz et al., 1994) .
The genetic analysis of mouse skin tumors induced in a controlled way by U.V.B.-irradiation has provided additional evidence for the causal involvement of p53 gene mutations. Several laboratories have analysed skin tumors (mainly SCCs) induced by U.V.B. in dierent mouse strains for mutations in the p53 gene (Kress et al., 1992; Kanjilal et al., 1993; Van Kranen et al., 1995) . Dierences in frequencies of p53 gene mutations between mouse genetic backgrounds were detected. However, our recently compiled mutational spectrum in the p53 gene from U.V.B.-induced hairless mouse skin tumors, resembles to a great extent the spectrum observed in human skin tumors (Dumaz et al., 1997) . In hairless mice, the majority of the detected mutations in the p53 gene were also C?T transitions, or (to a lesser extent) CC?TT double transitions. Most of the p53 mutations in these mice were found at dipyrimidine sites in the non-transcribed strand, which is in line with the observation that DNA repair of cyclobutane pyrimidine dimers on this strand is in-ecient in hairless mice (Ruven et al., 1994) .
We have recently generated mice with a defect in one of the genes involved in NER, i.e. the XPA gene . These XPA-de®cient mice display a skin cancer proneness that is highly comparable to that observed in human XP-A (De Berg et al., 1997) . To enable and facilitate the analysis of the eects of U.V.B. irradiation in more detail, the XPAde®cient mice were crossbred with hairless (HRA : SKH) mice. HRA : SKH mice have been extensively studied in U.V.-exposure experiments, and therefore, the relationship between U.V.B. irradiation and the carcinogenic response is well established (Ruven et al., 1994; De Gruijl and Forbes, 1995; Van Kranen et al., 1995; Dumaz et al., 1997) .
In the present study we show that, unexpectedly, hairless XPA-de®cient mice develop next to the usually observed actinic keratoses (AK) and SCCs, high numbers of papillomas on their skin after exposure to low levels of U.V.B. Moreover, papillomas were much more frequently found in the lowest dose group (32 J/m 2 /day) than in the highest dose group (80 J/m 2 / day). Surprisingly, we found in these skin papillomas of hairless XPA-de®cient mice a high frequency (11 out of 14) of ras gene mutations, resembling one of the genetic changes observed in chemically-induced mouse skin papillomas (Brown et al., 1990; 1995) . In contrast to the carcinomas found in repair pro®cient hairless mice, the tumors found in XPA-de®cient mice (both in papillomas and carcinomas) displayed a very low incidence of mutations in the conserved domains of the p53 gene. These results will be discussed in relation to the present views on the pathogenesis of human and murine skin cancer.
Results

U.V.B.-induced skin tumorigenesis
Hairless XPA
7/7
, XPA +/+ and XPA +/7 mice were exposed to daily doses of either 32 J/m 2 or 80 J/m 2 of U.V.B. The highest daily dose of 80 J/m 2 is slightly below the dose that causes acute eects (such as erythema and oedema) on the skin of hairless XPA 7/7 mice.
As is shown in Figure 1 daily exposure of hairless XPA 7/7 mice to these low doses of U.V.B. resulted in the development of skin tumors with a short latency time and a 100% prevalence. /day), all XPA-de®cient mice had developed one or more tumors. At these time points, the accumulated doses were 10.3 kJ/m 2 and 4.6 kJ/m 2 for the two exposure groups, respectively. In comparison, in previous studies (De Gruijl and Forbes, 1995; Van Kranen et al., 1995) mice. For further details on dose-time relationships in comparison to wild type mice see Berg et al., (1997) .
U.V.B. radiation induces an altered skin tumor spectrum in XPA-de®cient mice Animals carrying tumors with a size 54 mm were removed from the experiment, and in total, 83 randomly isolated tumors were histopathologically characterized. Hairless XPA 7/7 mice developed papillomas, actinic keratosis (AK), and invasive squamous cell carcinomas (SCC) on their U.V.B.-exposed skin. Once mice had developed a tumor 52 mm in size, they were counted. One animal exposed to 32 J/m 2 /day died of unknown reasons before the ®rst skin tumor in this exposure group was detected, and was, therefore, excluded from the experiment The papillomas also often displayed focal features of AK-like dysplasia.
It has been described that the development of AK and SCC occurs frequently in hairless mouse strains after exposure to U.V.B. (De Gruijl and Forbes, 1995; Van Kranen et al., 1995) . In contrast, papilloma development upon U.V.B. irradiation is a rare event (55%) in these mice (Berg et al., 1993; De Gruijl and Forbes, 1995) . Interestingly, the development of the dierent tumor types seemed to be in¯uenced by the U.V.B. dose to which the mice were exposed. As is shown in Figure 2 , a relatively high amount of papillomas was observed on the skin of XPA 7/7 mice exposed to 32 J/m 2 /day (31%, versus 10% on the skin of mice exposed to 80 J/m 2 /day). The majority of the tumors, isolated from XPA 7/7 mice exposed to 80 J/ m 2 /day, were SCCs (56%). The number of AKs encountered on the skin of XPA 7/7 mice appeared to be somewhat higher in mice exposed to 32 J/m 2 /day. In summary, more malignant skin tumors were found on the skin of XPA 7/7 mice exposed to the highest U.V.B. dose, whereas on the skin of XPA 7/7 mice exposed to the lower dose, more benign tumors and precursor lesions like AK were observed. Apparently, a defect in the XPA gene in hairless mice led to a U.V.B. doserelated distribution of skin tumor types.
p53 status in skin tumors of XPA-de®cient mice Mutations in the p53 tumor suppressor gene have been frequently found in both human and murine SCCs. In skin tumors isolated from XP patients, an increased frequency of U.V. characteristic mutations in the p53 gene, i.e. C?T and especially CC?TT transitions (450%), was observed. Interestingly, it appeared that the p53 mutation spectrum in skin tumors isolated from XP patients diered from that found in skin tumors of non-XP individuals (Sato et al., 1993; Dumaz et al., 1994) . To explore the involvement of the p53 gene in murine XP skin carcinogenesis, we analyzed the tumors obtained in this study both immunohistochemically and by DNA sequence analysis.
p53 protein levels were visualized by immunostaining of tumor sections with the CM-5 polyclonal antibody. Immunostaining was detectable in app. 70% of all analysed tumors isolated from XPA 7/7 mice, but intensities varied among the tumors. In papillomas, the less dierentiated basal cells stained clearly, leading to a distinct linear pattern of staining con®ned to the basal cell layer (Figure 3a) . Also in SCCs and AKs a linear pattern was detectable in approximately 20% of these tumors (Figure 3b ). In the majority of AKs and SCCs patches of positively stained nuclei were present, whereas in other parts of the tumor staining was not observed ( Figure 3c) ; a phenomenon also found in U.V.A. (365 nm) radiation-induced carcinomas . Intensive staining homogeneously spread throughout the tumor, comparable to that found in tumors of hairless wild-type mice (Van Kranen et al., 1995) , was only present in approximately 15% of all tumors analysed (Figure 3d) . Frequently, foci with positive p53 staining were also observed in skin compartments next to the tumor site, possibly indicative for the presence of persisting DNA damage.
The DNA sequence of exons 5, 7 and 8 of the p53 gene was determined in a total of 37 collected tumors of U.V.B.-irradiated hairless XPA 7/7 mice. In SCCs (n=8) and papillomas (n=5) isolated from mice that were daily exposed to 32 J/m 2 , no mutations in these exons of the p53 gene could be detected. Only in three tumors out of 24, isolated from XPA-de®cient mice that were daily exposed to 80 J/m 2 , p53 gene mutations were detected (Table 1 ). In total, in 8% (3 out of 37) of the skin tumors of XPA-de®cient mice that were analysed, a mutation in the examined exons of the p53 gene was detected (Table 1 ). In contrast, in 11 tumors isolated from XPA +/+ and XPA +/7 littermate mice, that were daily exposed to 80 J/m 2 for a much longer time period , we observed ®ve mutations (45%). The mutational analysis in these tumors was restricted to exon 8 only, since it has been reported that in wild-type HRA : SKH mice, p53 gene mutations are predominantly present in this exon (Van Kranen et al., 1995; Dumaz et al., 1997) .
The p53 mutations detected in tumors from XPA 7/7
, XPA +/+ , and XPA +/7 mice, are shown in Table 2 . In tumors isolated from the XPA 7/7 mice, two mutations were detected in exon 8 (SCC), and one mutation was found in exon 5 (papilloma). These three p53 gene mutations were found to occur infrequently in U.V.B.-induced skin tumors isolated from wild-type HRA : SKH mice. In contrast, four of the ®ve p53 gene mutations encountered in skin tumors of the 
XPA
+/+ and XPA +/7 mice appeared to be hot-spot mutations, that are frequently observed in skin tumors of wild-type HRA : SKH mice (Dumaz et al., 1997) .
All 8 mutations detected resulted in amino acid changes, and were almost exclusively C?T transitions that are characteristic for U.V.-induced mutagenesis. No CC?TT mutations, nor small insertions or deletions, were found. All mutations occurred at dipyrimidine sequences, and are assumed to originate from the non-transcribed strand, with the notable exception of the mutation detected in codon 260 in a SCC of a XPA 7/7 mouse (indicating the loss of strand bias repair in XPA 7/7 mice).
ras gene mutation analysis
The unexpected observation that U.V.B. radiation induced a high number of skin papillomas in XPAde®cient mice (Figure 2) , combined with the fact that ras gene mutations are commonly found in chemicallyinduced mouse skin papillomas, prompted us to examine the tumors of XPA-de®cient mice also for the presence of ras gene mutations. Codons 12 and 13 of the H-, K-and N-ras genes were examined for the presence of relevant (U.V.B.-inducible) mutations. A typical example of such an analysis of the H12-ras codon is given in Figure 4 . In 10 out of 14 papillomas and in one out of 14 SCCs analysed, we observed a G?A transition in the non-transcribed strand. This mutation is most likely caused by an U.V.B.-induced C?T transition at a dipyrimidine site in the transcribed strand of the H-ras gene. All mutations were found at the 2nd position of the 12th codon (rather than on the 1st position, see Figure 4 ). This latter ®nding also holds for ras gene mutations at the same codon in for instance MNNG-or MNU-induced mouse skin tumors (Mitra et al., 1989; Brown et al., 1990 Brown et al., , 1995 . Further analysis of the same set of 28 tumors revealed that additionally one papilloma and one SCC carried a K12-ras gene mutation (also a G?A transition at the 2nd position of the codon, results not shown). Mutations found by the dot blot assay were con®rmed by DNA sequence analysis. 
Discussion
Our ®nding that the development of dierent tumor types in XPA-de®cient mice appeared to be U.V.B. dose dependent and furthermore involved dierent genetic events, raises the interesting possibility that these dierent tumor types originate from dierent target cells. Supportive to this notion is that a ras gene mutation apparently is advantageous to papilloma development, whereas it is not for U.V.-induced SCCs (Figure 4 ). This makes it unlikely that U.V.B.-induced skin papillomas in XPA-de®cient mice are obligatory precursors to SCCs. In this respect these U.V.B.-induced papillomas resemble the low risk skin papillomas induced by some alkylating agents in wild type mice (Brown et al., 1990 (Brown et al., , 1995 . Important questions to be answered are: (i) why did papillomas develop upon U.V.B. exposure only in XPA-de®cient hairless mice and virtually not in wild type mice?; (ii) why did papillomas appear less abundant at higher U.V.B. doses in XPA-de®cient mice?; (iii) what could be the reason that we found such a low incidence of p53 gene mutations in tumors of XPA-de®cient mice, this in contrast to wild type mice, humans and XP patients? and (iv) which genes (other then p53) are advantageous to SCC development in XPA-de®cient mice? As for (i) the papilloma development we should consider the complete absence of DNA repair in XPAde®cient mice. A primary U.V.B. target in XPAde®cient mice appeared to be a dipyrimidine site in the transcribed strand of the H-ras gene. In wild type mice a U.V.B.-induced pyrimidine dimer at this site will be repaired eciently by a mechanism known as transcription coupled repair (TCR, Lehmann, 1995) . However, in XPA-de®cient mice this repair pathway is defective, and this could well lead to a C?T transition in this normally eciently repaired DNA strand. This ®nding might give an explanation (see also Figure 5 ) for the long-standing discrepancy that papillomas only develop eciently in chemically-treated mouse skins, and virtually not after U.V.B. exposure. Alkylating agents, for example, when applied on the skin of wild type mice, induce papillomas by targeting the 2nd G residue in codon 12 of the H-ras gene, resulting in a G?A transition like we found in U.V.B.-induced papillomas of XPA-de®cient mice ( Figure 5 and references. Mitra et al., 1989; Brown et al., 1990 Brown et al., , 1995 . Furthermore, the main genetic target of the classical skin carcinogen DMBA in papilloma development, is an A-residue in codon 61 of the mouse Hras gene (Brown et al., 1995) . DMBA-induced as well as U.V.B.-induced DNA damages, are thought to be repaired by the nucleotide excision repair pathway. The target A-residue is located in the poorly repaired nontranscribed strand, and may, therefore in wild type as well as in XPA-de®cient mice, easily become mutated, leading to the observed (activating) A?T transversion ( Figure 5 ). Mutations in codon 61 were not found in tumors of U.V.B.-treated XPA-de®cient mice, possibly because this codon harbours a poorly mutable dithymidine U.V.B. target in the transcribed strand ( Figure 5) .
As for the question (ii) why skin (low risk) papillomas did appear less frequently at higher U.V.B. doses in XPA-de®cient mice, it is reasonable to assume that at higher U.V.B. doses, due to the absence of DNA repair, the overall DNA damage becomes critical and (low risk) initiated cells (e.g. suprabasal cells) become apoptotic. Preliminary results obtained by us (unpublished) and others (MiyauchiHashimoto et al., 1996) , indeed showed that the skin of XPA-de®cient mice becomes highly apoptotic at doses of 4100 J/m 2 /day. In line with these observations are the results of Lungmann and Zhang (1996, and references therein) , who showed that cell lines of human XP-A patients dramatically respond to U.V.B., in the sense that they easily become apoptotic in a p53-dependent manner. Possibly, at higher U.V.B. doses other target cells (more shielded from radiation, e.g. basal or hair-follicle cells) become initiated and The transcribed (+) and non-transcribed (7) As a control for the procedure ampli®ed DNA was also hybridized with a wild type oligonucleotide (GGA, left panel). Samples nos. 29 and 30 were a positive control (DNA of a tumor carrying a GGA ? GAA H12-ras gene mutation) and a negative control (DNA of normal untreated skin), respectively these cells might escape from apoptosis. In line with this hypothesis is our ®nding that p53 gene mutations (although low in number) were only found in tumors of XPA-de®cient mice, that were exposed to the highest U.V.B. dose (Tables 1 and 2 ). Our data suggest that skin tumor development upon U.V.B. treatment in hairless XPA-de®cient mice was less dependent on alterations in the p53 gene as compared to that in their wild-type counterparts (iii, see also Dumaz et al., 1997) . This seems to be in disagreement with frequencies of p53 gene mutations observed in human XP skin tumors (Sato et al., 1993; Dumaz et al., 1994) . However, it was shown that the frequency of mutations in the p53 gene in human XP skin tumors correlated with the size and malignant character of the tumor (Matsumura et al., 1995) . This might suggest that, other than in normal individuals (Ziegler et al., 1994) , mutations in the p53 gene could be a late event in XP skin tumorigenesis. However, comparative studies between XP and non-XP humans are always hampered by the limited number of available XP patients, dierent sun exposures and unde®ned genetic backgrounds (including the various XP complementation groups; note that the majority of the XP data was obtained from XP-C patients; Dumaz et al., 1994) . Therefore, the low incidence of p53 gene mutations in murine XP-A tumors found in this study, may well be due to the low (accumulated) U.V.B. dose given, the (early) progression stage of the isolated SCCs, or the XP complementation group under study. Worthwhile mentioning in this respect is the recent ®nding (Ananthaswamy, personal communication) that U.V.B.-induced skin tumors of XPC-de®cient mice carry a high portion of CC?TT double transitions in the p53 gene. Furthermore, CC?TT double transitions in human XP originate mainly from patients belonging to complementation group C (Dumaz, personal communication) . These ®ndings, at least in part, support the idea that our aberrant murine data on p53 mutation frequency and spectrum in XPA-de®cient mice, may be caused by dierences in XP complementation groups. However, although our immunohistochemical data seem to support a marginal involvement of p53 in low dose U.V.B. skin carcinogenesis in hairless XPA-de®cient mice (Figure 3) , we can not exclude completely the possibility that some (non hotspot) p53 gene mutations remained undetected, since we only analysed the p53 exons targeted in wild types (i.e. exons 5, 7 and 8).
If p53 is not the primary oncogenic target in U.V.B.-driven skin carcinogenesis in XPA-de®cient mice, which gene is involved (iv)? A feasible genetic route to SCC development might be the induction of gene mutations that generate cells that are defective in an apoptotic response. In wild type mice (and in humans) mutations in the p53 gene are thought to be necessary early events in this respect (Ziegler et al., 1994) . However, genes that are not normally a target for U.V.B., as a consequence of strand bias in repair, might become mutable targets in XPA-de®cient mice (e.g. like the H-ras gene in papilloma development). Such gene mutations can give rise to initiating events, e.g a p53-independent escape from apoptosis. Exposure of XPA-de®cient mice to higher U.V.B. doses may still lead to p53 gene mutations (Tables 1 and 2) , which might further facilitate tumor outgrowth or progression, a phenomenon also found in human XP (Matsumura et al., 1995) . As a consequence, depending on the time point at which the p53 gene becomes mutated, the tumor mass is heterogeneous, harboring areas consisting of p53 mutant cells and p53 wild-type cells. Supportive to this is the fact that we found a Figure 5 Tentative model for genetic changes occurring at codon 12 or 61 of the H-ras gene during U.V.B.-or chemically-induced skin papilloma development in both wild type and XPA-de®cient mice (for details see text). nts=non transcribed strand; ts=transcribed strand number of tumors that showed patches of nuclei highly positive for the p53 protein, whereas other parts were negative (Figure 3 ). In addition, approximately 30% of the tumors of hairless XPA-de®cient mice were entirely negative in immunostaining, indicating that p53 gene point mutations did not occur at all in these tumors.
In summary, it seems that in hairless XPA-de®cient mice, when exposed to low U.V.B. doses, mutations in the p53 gene are not that essential for tumor development as they appear to be in repair pro®cient HRA : SKH mice. Other genes, possibly also involved in cell cycle control and/or apoptosis, might become the primary targets for U.V.B.-driven carcinogenesis in XPA-de®cient mice. One set of genes was identi®ed in the present study, i.e the ras gene family, although mutations in these genes appeared to result in mainly papilloma development. Future studies will focus on the identi®cation of other genes that play a role in U.V.B.-induced skin carcinogenesis in XPA-de®cient mice, and possibly also in wild type mice and humans.
Materials and methods
Mice
The generation of XPA-de®cient mice by gene targeting in embryonic stem cells has been described previously . XPA-de®cient mice were crossbred with albino hairless mice (HRA : SKH inbred strain), to obtain hairless XPA +/+ , XPA +/7 and XPA 7/7 mice. Genotypes of the mice were determined by PCR analysis of DNA isolated from tail tips. Three primers were used: XP26 5'GTGTCAGGCATAAGATCTATGACAA3', XP47 5'A-GGCAAGCACCTGCAGCTGT3' and PGK2 5'GGCCAC-TTGTGTAGCGCCAA3'. The targeted allele was identi®ed as a 132 bp PCR fragment (the PGK2 primer is situated in the PGK promoter, and the XP26 primer is situated in intron 2 of the XPA gene). The wild-type allele was identi®ed as a 214 bp PCR fragment (the XP47 primer is situated over splice-site intron/exon 3 of the XPA gene and XP26). All mice (both females and males) were 6 to 10 weeks of age at the start of the experiment. mice (littermates, n=14 for each genotype) were daily irradiated with U.V. (range 250 ± 400 nm) for 6 min at dose rates of 0.089 and 0.22 J/m 2 .s 71 using American Philips F40 sunlamps (daily accumulated doses of 32 J/m 2 and 80 J/m 2 , respectively). The main output of the lamps is between 280 ± 380 nm (borders at 1% of maximum output). The carcinogenic eectiveness lies between 290 ± 310 nm, with a maximum at 297 nm . Control (non-irradiated) groups consisted of eight mice of each of the three genotypes. All mice were checked twice weekly for the development of tumors. Mice carrying tumors 54 mm in size were withdrawn from the U.V.B. exposure at least 48 h prior to the tumor isolation. Mice were sacri®ced, and the tumors were carefully removed. For histology and immunohistochemical staining, one portion of the tumor was formalin ®xed for approximately 4 h, stored in 70% ethanol and paran embedded according to routine procedures. For histological analysis, deparanized 5 mm sections were subsequently stained with haematoxylin and eosin. The other portion of the tumor was snap frozen in liquid N 2 and stored at 7708C for molecular analysis. After careful dissection of normal skin tissue to enrich for tumor tissue, genomic DNA was isolated (QIAamp Tissue Kit 250, Qiagen) for mutation analysis in the p53 or ras gene.
Immunohistochemistry
Staining for p53 expression was performed on deparaffinized 5 mm sections of the embedded tumors with the CM-5 rabbit polyclonal antibody, raised against the mouse p53 protein (kindly provided by Dr David Lane). Sections were counterstained with haematoxylin and eosin. The exact procedure has been extensively described previously by Berg et al., (1996) .
Detection of p53 gene mutations
Exons 5,7 and 8 of the p53 gene of DNA isolated from skin tumors, were individually ampli®ed and subsequently sequenced using a procedure described previously (Van Kranen et al., 1995) . The cycle-sequencing reactions were performed with Thermo-Sequenase (Amersham) according to the manufacturers protocol.
Detection of ras gene mutations
Relevant codons of the ras gene family, containing a dipyrimidine site on either strand, i.e. H12-, K12-, N12-, H13-, K13 and N13, were analysed for the presence of activating point mutations using a dot-blot procedure as described previously (Van Kranen et al., 1995) . Filters were applied, using a 1 h prehybridization step at 568C, followed by O/N hybridization with 10 pmole of 3'-DIG end labeled allele speci®c oligonucleotide (®nal volume 5 ml). For detection, an anti-DIG-AP conjugate antibody with CPD-Star as a substrate (both Boehringer) were used, according to the manufacturers protocol.
For con®rmation the same samples were also analysed by direct sequencing. Amplimers were extended with M13 sequences and direct sequencing of the PCR fragments was identical to the procedure described earlier (Van Kranen et al., 1995 Abbreviations U.V.B., ultra violet B; XPA, xeroderma pigmentosum complementation group A correcting gene; XP, xeroderma pigmentosum; SCC, squamous cell carcinoma; DMBA, 7, anthracene; MNU, methylnitrosourea; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine.
